BioCentury
ARTICLE | Company News

FDA approves Servier's ALL therapy acquired in Shire deal

December 21, 2018 7:37 PM UTC

FDA approved Asparlas calaspargase pegol-mknl (formerly SHP663) from Servier (Suresnes, France) to treat acute lymphoblastic leukemia in patients ages one month to 21 years old.

The pegylated L-asparaginase is approved as part of a multiagent chemotherapeutic regimen for ALL...

BCIQ Company Profiles

Servier

Shire plc